[Effect of hypoglycemic drugs on hemorheological parameters].

The hemorheological activity of a series of hypoglycemic drugs and the new antidiabetic agent RU-254 (9-diethylaminoethyl-2,3-dihydroimidazo[1, 2-a]benzimidazole dihydrochloride) was studied by comparative tests on rats with model diabetes. All the tested drugs reduce the number of ADP-activated platelet forms, inhibit platelet aggregation, and decrease the blood viscosity in both intact rats and the animals with streptosotocin-induced diabetes. RU-254 exhibited maximum activity with respect to a complex of hemorheological parameters. Glyclazide was less effective in this respect than RU-254, but exceeded the activity of both glybenclamide and glydifen.